Effectiveness of milnacipran for the treatment of chronic pain in the orofacial region
The effect of milnacipran for the treatment of chronic pain in the orofacial region, including burning mouth syndrome (BMS) and atypical odontalgia (AO), was assessed while accounting for the influence of concurrent depressive symptoms on the pain-relieving effect. Milnacipran was administered for 1...
Gespeichert in:
| Veröffentlicht in: | Clinical neuropharmacology 2010-03, Vol.33 (2), p.79-83 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 83 |
|---|---|
| container_issue | 2 |
| container_start_page | 79 |
| container_title | Clinical neuropharmacology |
| container_volume | 33 |
| creator | Ito, Mikiko Kimura, Hiroyuki Yoshida, Keizo Kimura, Yuki Ozaki, Norio Kurita, Kenichi |
| description | The effect of milnacipran for the treatment of chronic pain in the orofacial region, including burning mouth syndrome (BMS) and atypical odontalgia (AO), was assessed while accounting for the influence of concurrent depressive symptoms on the pain-relieving effect.
Milnacipran was administered for 12 weeks to 36 patients with chronic pain in the orofacial region (3 men and 29 women, aged between 22 and 76 years with a mean age of 59 years). Of those patients, 22 and 10 patients had BMS and AO, respectively. The initial dose of milnacipran was 15 mg a day, and the dose was raised up to 100 mg a day. Pain was assessed using the visual analog scale, and symptoms of depression were evaluated using the Hamilton Depression Rating Scale at baseline and at weeks 1, 2, 4, 6, 8, 10, and 12 of the study treatment.
Data from 32 patients who completed the study were included in the analysis. The visual analog scale score significantly decreased after the 12-week treatment, and it showed a similar time course of decline irrespective of concurrent depressive symptoms during the 12 weeks.
Treatment with milnacipran resulted in a significant improvement of chronic pain in the orofacial region irrespective of concurrent symptoms of depression. The present results suggested that milnacipran may be an effective agent for treatment of such disorders. |
| doi_str_mv | 10.1097/wnf.0b013e3181cb5793 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_807285292</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>733645255</sourcerecordid><originalsourceid>FETCH-LOGICAL-c404t-79bd0139fe57d59dcc80574e939ed565260e01a5866c7141f747469498fe17a13</originalsourceid><addsrcrecordid>eNqFkEtPwzAQhC0EoqXwDxDKjVOK346PqGoBqYILr1vkOGsalNjFTkH8e1IVOHBBWmkv38zuDEKnBE8J1uriw7sprjBhwEhBbCWUZntoTARTOZH0eR-NMZM0F1LyETpK6RVjXGiuD9GIYqaEFHKMHufOge2bd_CQUhZc1jWtN7ZZR-MzF2LWryDrI5i-A99vAbuKwTc2W5vGZ8NsgRCDG0SmzSK8NMEfowNn2gQn33uCHhbz-9l1vry7upldLnPLMe9zpat6SKAdCFULXVtbYKE4aKahHh6kEgMmRhRSWkU4cYorLocMhQOiDGETdL7zXcfwtoHUl12TLLSt8RA2qSywooWgmv5LKsYkF1SIgeQ70saQUgRXrmPTmfhZElxuqy-fbhfl3-oH2dn3gU3VQf0r-umafQEjR4AE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>733645255</pqid></control><display><type>article</type><title>Effectiveness of milnacipran for the treatment of chronic pain in the orofacial region</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>Ito, Mikiko ; Kimura, Hiroyuki ; Yoshida, Keizo ; Kimura, Yuki ; Ozaki, Norio ; Kurita, Kenichi</creator><creatorcontrib>Ito, Mikiko ; Kimura, Hiroyuki ; Yoshida, Keizo ; Kimura, Yuki ; Ozaki, Norio ; Kurita, Kenichi</creatorcontrib><description>The effect of milnacipran for the treatment of chronic pain in the orofacial region, including burning mouth syndrome (BMS) and atypical odontalgia (AO), was assessed while accounting for the influence of concurrent depressive symptoms on the pain-relieving effect.
Milnacipran was administered for 12 weeks to 36 patients with chronic pain in the orofacial region (3 men and 29 women, aged between 22 and 76 years with a mean age of 59 years). Of those patients, 22 and 10 patients had BMS and AO, respectively. The initial dose of milnacipran was 15 mg a day, and the dose was raised up to 100 mg a day. Pain was assessed using the visual analog scale, and symptoms of depression were evaluated using the Hamilton Depression Rating Scale at baseline and at weeks 1, 2, 4, 6, 8, 10, and 12 of the study treatment.
Data from 32 patients who completed the study were included in the analysis. The visual analog scale score significantly decreased after the 12-week treatment, and it showed a similar time course of decline irrespective of concurrent depressive symptoms during the 12 weeks.
Treatment with milnacipran resulted in a significant improvement of chronic pain in the orofacial region irrespective of concurrent symptoms of depression. The present results suggested that milnacipran may be an effective agent for treatment of such disorders.</description><identifier>ISSN: 0362-5664</identifier><identifier>EISSN: 1537-162X</identifier><identifier>DOI: 10.1097/wnf.0b013e3181cb5793</identifier><identifier>PMID: 20375656</identifier><language>eng</language><publisher>United States</publisher><subject>Adrenergic Uptake Inhibitors - therapeutic use ; Adult ; Aged ; Burning Mouth Syndrome - complications ; Burning Mouth Syndrome - drug therapy ; Chronic Disease ; Cyclopropanes - therapeutic use ; Depression - complications ; Depression - drug therapy ; Dose-Response Relationship, Drug ; Facial Pain - complications ; Facial Pain - drug therapy ; Female ; Humans ; Male ; Middle Aged ; Serotonin Uptake Inhibitors - therapeutic use ; Toothache - complications ; Toothache - drug therapy</subject><ispartof>Clinical neuropharmacology, 2010-03, Vol.33 (2), p.79-83</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c404t-79bd0139fe57d59dcc80574e939ed565260e01a5866c7141f747469498fe17a13</citedby><cites>FETCH-LOGICAL-c404t-79bd0139fe57d59dcc80574e939ed565260e01a5866c7141f747469498fe17a13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20375656$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ito, Mikiko</creatorcontrib><creatorcontrib>Kimura, Hiroyuki</creatorcontrib><creatorcontrib>Yoshida, Keizo</creatorcontrib><creatorcontrib>Kimura, Yuki</creatorcontrib><creatorcontrib>Ozaki, Norio</creatorcontrib><creatorcontrib>Kurita, Kenichi</creatorcontrib><title>Effectiveness of milnacipran for the treatment of chronic pain in the orofacial region</title><title>Clinical neuropharmacology</title><addtitle>Clin Neuropharmacol</addtitle><description>The effect of milnacipran for the treatment of chronic pain in the orofacial region, including burning mouth syndrome (BMS) and atypical odontalgia (AO), was assessed while accounting for the influence of concurrent depressive symptoms on the pain-relieving effect.
Milnacipran was administered for 12 weeks to 36 patients with chronic pain in the orofacial region (3 men and 29 women, aged between 22 and 76 years with a mean age of 59 years). Of those patients, 22 and 10 patients had BMS and AO, respectively. The initial dose of milnacipran was 15 mg a day, and the dose was raised up to 100 mg a day. Pain was assessed using the visual analog scale, and symptoms of depression were evaluated using the Hamilton Depression Rating Scale at baseline and at weeks 1, 2, 4, 6, 8, 10, and 12 of the study treatment.
Data from 32 patients who completed the study were included in the analysis. The visual analog scale score significantly decreased after the 12-week treatment, and it showed a similar time course of decline irrespective of concurrent depressive symptoms during the 12 weeks.
Treatment with milnacipran resulted in a significant improvement of chronic pain in the orofacial region irrespective of concurrent symptoms of depression. The present results suggested that milnacipran may be an effective agent for treatment of such disorders.</description><subject>Adrenergic Uptake Inhibitors - therapeutic use</subject><subject>Adult</subject><subject>Aged</subject><subject>Burning Mouth Syndrome - complications</subject><subject>Burning Mouth Syndrome - drug therapy</subject><subject>Chronic Disease</subject><subject>Cyclopropanes - therapeutic use</subject><subject>Depression - complications</subject><subject>Depression - drug therapy</subject><subject>Dose-Response Relationship, Drug</subject><subject>Facial Pain - complications</subject><subject>Facial Pain - drug therapy</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Serotonin Uptake Inhibitors - therapeutic use</subject><subject>Toothache - complications</subject><subject>Toothache - drug therapy</subject><issn>0362-5664</issn><issn>1537-162X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkEtPwzAQhC0EoqXwDxDKjVOK346PqGoBqYILr1vkOGsalNjFTkH8e1IVOHBBWmkv38zuDEKnBE8J1uriw7sprjBhwEhBbCWUZntoTARTOZH0eR-NMZM0F1LyETpK6RVjXGiuD9GIYqaEFHKMHufOge2bd_CQUhZc1jWtN7ZZR-MzF2LWryDrI5i-A99vAbuKwTc2W5vGZ8NsgRCDG0SmzSK8NMEfowNn2gQn33uCHhbz-9l1vry7upldLnPLMe9zpat6SKAdCFULXVtbYKE4aKahHh6kEgMmRhRSWkU4cYorLocMhQOiDGETdL7zXcfwtoHUl12TLLSt8RA2qSywooWgmv5LKsYkF1SIgeQ70saQUgRXrmPTmfhZElxuqy-fbhfl3-oH2dn3gU3VQf0r-umafQEjR4AE</recordid><startdate>201003</startdate><enddate>201003</enddate><creator>Ito, Mikiko</creator><creator>Kimura, Hiroyuki</creator><creator>Yoshida, Keizo</creator><creator>Kimura, Yuki</creator><creator>Ozaki, Norio</creator><creator>Kurita, Kenichi</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7TK</scope><scope>7U7</scope><scope>C1K</scope></search><sort><creationdate>201003</creationdate><title>Effectiveness of milnacipran for the treatment of chronic pain in the orofacial region</title><author>Ito, Mikiko ; Kimura, Hiroyuki ; Yoshida, Keizo ; Kimura, Yuki ; Ozaki, Norio ; Kurita, Kenichi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c404t-79bd0139fe57d59dcc80574e939ed565260e01a5866c7141f747469498fe17a13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Adrenergic Uptake Inhibitors - therapeutic use</topic><topic>Adult</topic><topic>Aged</topic><topic>Burning Mouth Syndrome - complications</topic><topic>Burning Mouth Syndrome - drug therapy</topic><topic>Chronic Disease</topic><topic>Cyclopropanes - therapeutic use</topic><topic>Depression - complications</topic><topic>Depression - drug therapy</topic><topic>Dose-Response Relationship, Drug</topic><topic>Facial Pain - complications</topic><topic>Facial Pain - drug therapy</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Serotonin Uptake Inhibitors - therapeutic use</topic><topic>Toothache - complications</topic><topic>Toothache - drug therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ito, Mikiko</creatorcontrib><creatorcontrib>Kimura, Hiroyuki</creatorcontrib><creatorcontrib>Yoshida, Keizo</creatorcontrib><creatorcontrib>Kimura, Yuki</creatorcontrib><creatorcontrib>Ozaki, Norio</creatorcontrib><creatorcontrib>Kurita, Kenichi</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><jtitle>Clinical neuropharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ito, Mikiko</au><au>Kimura, Hiroyuki</au><au>Yoshida, Keizo</au><au>Kimura, Yuki</au><au>Ozaki, Norio</au><au>Kurita, Kenichi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effectiveness of milnacipran for the treatment of chronic pain in the orofacial region</atitle><jtitle>Clinical neuropharmacology</jtitle><addtitle>Clin Neuropharmacol</addtitle><date>2010-03</date><risdate>2010</risdate><volume>33</volume><issue>2</issue><spage>79</spage><epage>83</epage><pages>79-83</pages><issn>0362-5664</issn><eissn>1537-162X</eissn><abstract>The effect of milnacipran for the treatment of chronic pain in the orofacial region, including burning mouth syndrome (BMS) and atypical odontalgia (AO), was assessed while accounting for the influence of concurrent depressive symptoms on the pain-relieving effect.
Milnacipran was administered for 12 weeks to 36 patients with chronic pain in the orofacial region (3 men and 29 women, aged between 22 and 76 years with a mean age of 59 years). Of those patients, 22 and 10 patients had BMS and AO, respectively. The initial dose of milnacipran was 15 mg a day, and the dose was raised up to 100 mg a day. Pain was assessed using the visual analog scale, and symptoms of depression were evaluated using the Hamilton Depression Rating Scale at baseline and at weeks 1, 2, 4, 6, 8, 10, and 12 of the study treatment.
Data from 32 patients who completed the study were included in the analysis. The visual analog scale score significantly decreased after the 12-week treatment, and it showed a similar time course of decline irrespective of concurrent depressive symptoms during the 12 weeks.
Treatment with milnacipran resulted in a significant improvement of chronic pain in the orofacial region irrespective of concurrent symptoms of depression. The present results suggested that milnacipran may be an effective agent for treatment of such disorders.</abstract><cop>United States</cop><pmid>20375656</pmid><doi>10.1097/wnf.0b013e3181cb5793</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0362-5664 |
| ispartof | Clinical neuropharmacology, 2010-03, Vol.33 (2), p.79-83 |
| issn | 0362-5664 1537-162X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_807285292 |
| source | MEDLINE; Journals@Ovid Complete |
| subjects | Adrenergic Uptake Inhibitors - therapeutic use Adult Aged Burning Mouth Syndrome - complications Burning Mouth Syndrome - drug therapy Chronic Disease Cyclopropanes - therapeutic use Depression - complications Depression - drug therapy Dose-Response Relationship, Drug Facial Pain - complications Facial Pain - drug therapy Female Humans Male Middle Aged Serotonin Uptake Inhibitors - therapeutic use Toothache - complications Toothache - drug therapy |
| title | Effectiveness of milnacipran for the treatment of chronic pain in the orofacial region |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-20T07%3A47%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effectiveness%20of%20milnacipran%20for%20the%20treatment%20of%20chronic%20pain%20in%20the%20orofacial%20region&rft.jtitle=Clinical%20neuropharmacology&rft.au=Ito,%20Mikiko&rft.date=2010-03&rft.volume=33&rft.issue=2&rft.spage=79&rft.epage=83&rft.pages=79-83&rft.issn=0362-5664&rft.eissn=1537-162X&rft_id=info:doi/10.1097/wnf.0b013e3181cb5793&rft_dat=%3Cproquest_cross%3E733645255%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=733645255&rft_id=info:pmid/20375656&rfr_iscdi=true |